Information Provided By: 
Fly News Breaks for October 27, 2016
ABMD
Oct 27, 2016 | 13:24 EDT
BTIG analyst Sean Lavin said Abiomed is pulling back following the Q2 report due to a combination of high buy side expectations, seasonality, and maybe focus on pulling reps away from protected PCI. Lavin said there is no change in fundamentals and believes reimbursement changes and progress on the STEMI trial are more important long-term than a few million dollars. The analyst would buy Abiomed on the weakness and reiterates his Buy rating and $170 price target.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
